Positive mid-stage results for Takeda's dengue vaccine candidate

Takeda Pharmaceutical (TYO: 4502) says that data from an 18-month interim analysis of the ongoing Phase II DEN-204 trial of its live, attenuated tetravalent dengue vaccine candidate, TAK-003 (also referred to as TDV), have been published in The Lancet Infectious Diseases. The data showed increased seropositivity rates against dengue virus types 3 and 4 in children who were not previously exposed to infection.

The results of this interim analysis, a pre-planned evaluation of data from an ongoing trial, show that TAK-003 is associated with a reduction in the incidence of dengue in children and adolescents. These data were also presented yesterday at the American Society of Tropical Medicine and Hygiene Annual Meeting, says Takeda, Japan’s largest drugmaker.

“The reduced incidence of dengue in children and adolescents receiving TAK-003 is encouraging, however data from our ongoing Phase III efficacy trial, TIDES, are required to confirm these findings,” Derek Wallace, the lead at Takeda’s dengue program, said in a statement.